Clinical trials: Exudative Age-Related Macular Degeneration
Exudative Age-Related Macular Degeneration
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative…
- Trial name
- NCT01304693
- Testing
- ESBA1008 solution, Ranibizumab 0.5 mg
- Volunteers
- 376 people
- Sponsor
- Alcon Research
Non-Exudative Age Related Macular Degeneration
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
This is a Phase II/III,vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate non-exudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- McCP2/3 (NCT02127463)
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MacuCLEAR, Inc.
Exudative Age-Related Macular Degeneration
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative…
- Trial name
- ELOUAN (NCT02089503)
- Testing
- intravitreal injections of Lucentis
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Exudative Age-Related Macular Degeneration
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to…
- Trial name
- RACE (NCT01157065)
- Testing
- AL-78898A, Ranibizumab
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Alcon Research
Exudative Age-Related Macular Degeneration
A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
The primary objective of this proposed research study is to evaluate the safety of intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to intravitreal ranibizumab alone in the treatment of wet…
- Trial name
- Lucedex (NCT00793923)
- Testing
- ranibizumab and dexamethasone, Ranibizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Subhransu K. Ray, M.D., Ph.D.
Exudative Age-related Macular Degeneration
Long-term Follow-up of Subfoveal Neovascular AMD
Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study.
- Trial name
- NCT01608113
- Where
- Austria
- Volunteers
- 70 people
- Sponsor
- Medical University of Vienna
Exudative Age-related Macular Degeneration
Bevacizumab for Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many…
- Trial name
- NCT01306591
- Testing
- Bevacizumab 1, Bevacizumab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking University People's Hospital
Exudative Age Related Macular Degeneration
The Spectralis-Cirrus Study
Retinal thickness measurement is one of the most important examinations in the follow up of exudative age-related macular degeneration.
- Trial name
- NCT00927303
- Testing
- Cirrus-Spectralis, Spectralis-Cirrus
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery